News

Fluxergy was a founding member of the Industry Member Program (IPP) Wyss Diagnostic Accelerator (Wyss DxA). Wyss DxA is an initiative by the Wyss Institute at Harvard University to create and deliver breakthrough diagnostic technologies to meet unmet clinical needs in screening, diagnosis, prognosis, and treatment. Through participation in the IPP, Fluxergy is partnering with distinguished clinicians, researchers, engineers, funding agencies, philanthropists, government agencies, and industry partners.
“The measure of success for the Wyss Diagnostic Accelerator is saving lives by providing accurate and affordable diagnoses, and that is our mission,” said Dr. Rushdi Ahmad, Head of Wyss DxA.
Wyss DxA is led by Ahmad and Dr. David Walt. Walt is a leading faculty member at the Wyss Institute, professor of pathology at Brigham Hospital and Women’s Hospital, and scientific co-founder of several life sciences companies. By participating in the program, Fluxergy will work within the IPP to facilitate the discovery, development and delivery of diagnostic solutions in areas where the need is not being met.
“After my first meeting with the first partners, I was delighted. We have a space full of scientific and commercial weight to implement changes, especially to match unmet needs with desired technologies. The opportunity to join a team driven by the experience of a coalition of wealthy, passionate people is unique with such diverse expertise: applications in human health, veterinary medicine and food safety, global presence in every market and coverage of telemedicine, diagnostics, pharmaceutical discovery and digital health,” said Tej Patel, CEO and co-founder of Fluxergy.
Fluxergy aims to use its multi-modal diagnostic platform as an OEM partner to produce multi-ohm test panels that combine combinations of proteins, transcripts and metabolites into unique signatures to better inform patients about treatment outcomes. Examples of human health applications can be seen in infectious diseases, chronic blood diseases, cancer, sepsis, and chronic kidney disease. At present, healthcare devices may be limited to determining one type of parameter (i.e., immunoassay, chemistry, or PCR). Fluxergy’s flexible systems are designed to perform PCR, immunoassay, biochemistry and cell counting in one user-friendly platform. In healthcare, Fluxergy aims to help improve syndromic and situational test panels and make them available for use in small clinics, doctor’s offices, nursing homes and consumers for more sophisticated tests, from general metabolic panels to sepsis screening tests. This is an expansion of the central laboratory infrastructure that will facilitate faster clinical decision making based on laboratory information.
Dr. Ahmed concluded the year-end meeting by saying, “At Wyss Diagnostic Accelerator, this team has an unparalleled and unique vision to make diagnostics accessible to everyone.”
Fluxergy is a medical device company specializing in point-of-use detection technology to provide affordable diagnostics in any setting. The Fluxergy system uses proprietary microfluidics and a highly integrated sensor system to create a more flexible and cost-effective multimodal testing platform. Fluxergy is ISO 13485 and MDSAP certified for IVD production. Fluxergy’s manufacturing and R&D campus spans 90,000 sq.ft. Fluxergy’s manufacturing and R&D campus spans 90,000 sq.ft. Fluxergy’s manufacturing and research campus covers an area of ​​90,000 sq. ft. The Fluxergy manufacturing and research campus covers 90,000 square feet. in Irvine, California. Fluxergy Europe GMBH is based in Aschaffenburg, Germany. Fluxergy Inc. was founded in 2013 with the financial backing of lead investor and co-founder of Kingston Technology, John Tu.
The Fluxergy Diagnostic Test System consists of a Fluxergy Card, a disposable lab-on-a-chip test cartridge, a Fluxergy analyzer, and the Fluxergy Works software that runs the test process to view and interpret test data. Fluxergy cards are multi-modal (meaning different types of diagnostic tests can be performed at the same time, such as PCR, immunochemistry, chemistry, etc.) and are manufactured and designed using a proprietary printed circuit board (PCB), making them extremely cost-effective. and extensibility. Microfluidics. Fluxergy Works allows organizations to connect as many devices to the cloud as the network can support.
The Fluxergy POC PCR Test Kit COVID-19 is only available for purchase in the EU market and any other market that accepts CE marking as a valid regulatory approval.
Fluxergy is also developing a CLIA-free respiratory panel, an inflammation panel, and commercializes several products for the equine veterinary and food safety markets.
Contact the author: Contact information and available social information are listed in the upper right corner of all press releases.
© Copyright 1997-2015, Vocus PRW Holdings, LLC. Vocus, PRWeb and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.